Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPRX Catalyst Pharmaceuticals	$20.63 -2.1%	$21.29	$19.00 ▼ $26.58	$2.52B	0.7	1.31 million shs	1.39 million shs
GMTX Gemini Therapeutics	$60.35 +1.0%	$56.73	$1.16 ▼ $14.10	$2.61B	-0.12	189,291 shs	349,244 shs
IMVT Immunovant	$14.90 -2.3%	$16.38	$12.72 ▼ $34.47	$2.59B	0.66	1.46 million shs	614,356 shs
PROK ProKidney	$2.35 -2.7%	$2.29	$0.46 ▼ $7.13	$690.09M	1.76	5.63 million shs	690,808 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPRX Catalyst Pharmaceuticals	0.00%	+4.20%	+0.52%	-13.92%	+3.74%
GMTX Gemini Therapeutics	0.00%	+0.82%	-0.38%	+27.40%	+22.14%
IMVT Immunovant	0.00%	+0.13%	-10.09%	+5.39%	-52.99%
PROK ProKidney	0.00%	+2.12%	-26.75%	+239.15%	+0.84%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CPRX Catalyst Pharmaceuticals	4.8964 of 5 stars	3.6	1.0	0.0	3.9	3.5	3.3	3.8
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	2.9439 of 5 stars	4.4	2.0	0.0	0.0	2.6	1.7	0.0
PROK ProKidney	3.7226 of 5 stars	4.2	4.0	0.0	0.0	1.7	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CPRX Catalyst Pharmaceuticals	3.13	Buy	$33.20	60.93% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
IMVT Immunovant	2.83	Moderate Buy	$35.20	136.31% Upside
PROK ProKidney	2.33	Hold	$6.25	166.52% Upside

Current Analyst Ratings Breakdown

Latest PROK, IMVT, GMTX, and CPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	CPRX Catalyst Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/18/2025	PROK ProKidney	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/12/2025	IMVT Immunovant	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $37.00
8/12/2025	IMVT Immunovant	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$33.00 ➝ $30.00
8/11/2025	IMVT Immunovant	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/28/2025	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$17.00 ➝ $18.00
7/15/2025	PROK ProKidney	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $8.00
7/14/2025	PROK ProKidney	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $7.00
7/10/2025	IMVT Immunovant	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$18.00
7/9/2025	PROK ProKidney	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $9.00
6/30/2025	PROK ProKidney	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform	$3.00 ➝ $1.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CPRX Catalyst Pharmaceuticals	$558.50M	4.52	$2.39 per share	8.62	$6.10 per share	3.38
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.16 per share	N/A
PROK ProKidney	$80K	8,626.08	N/A	N/A	($3.41) per share	-0.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CPRX Catalyst Pharmaceuticals	$163.89M	$1.65	12.50	9.69	0.86	37.36%	40.78%	35.36%	11/5/2025 (Estimated)
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
IMVT Immunovant	-$413.84M	-$2.85	N/A	N/A	N/A	N/A	-80.99%	-72.23%	11/6/2025 (Estimated)
PROK ProKidney	-$61.19M	-$0.57	N/A	N/A	N/A	N/A	N/A	-17.11%	11/11/2025 (Estimated)

Latest PROK, IMVT, GMTX, and CPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	PROK ProKidney	-$0.14	-$0.13	+$0.01	-$0.13	N/A	$0.22 million
8/11/2025	Q1 2026	IMVT Immunovant	-$0.69	-$0.60	+$0.09	-$0.71	N/A	N/A
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CPRX Catalyst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CPRX Catalyst Pharmaceuticals	N/A	6.71	6.55
GMTX Gemini Therapeutics	N/A	71.49	71.49
IMVT Immunovant	N/A	12.32	12.32
PROK ProKidney	N/A	11.48	11.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CPRX Catalyst Pharmaceuticals	79.22%
GMTX Gemini Therapeutics	75.42%
IMVT Immunovant	47.08%
PROK ProKidney	51.59%

Insider Ownership

Company	Insider Ownership
CPRX Catalyst Pharmaceuticals	10.40%
GMTX Gemini Therapeutics	12.90%
IMVT Immunovant	1.80%
PROK ProKidney	41.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CPRX Catalyst Pharmaceuticals	80	122.39 million	109.66 million	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
IMVT Immunovant	120	174.32 million	171.18 million	Optionable
PROK ProKidney	3	294.28 million	172.18 million	Optionable

PROK, IMVT, GMTX, and CPRX Headlines

Recent News About These Companies

ProKidney (NASDAQ:PROK) Cut to Hold at Zacks Research

August 22 at 9:58 AM | marketbeat.com

ProKidney Corp. (NASDAQ:PROK) Sees Large Decline in Short Interest

August 21, 2025 | marketbeat.com

ProKidney (NASDAQ:PROK) Shares Down 6.9% - What's Next?

August 21, 2025 | marketbeat.com

ProKidney (NASDAQ:PROK) Stock Price Up 8.1% - Here's What Happened

August 20, 2025 | marketbeat.com

ProKidney (NASDAQ:PROK) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

August 15, 2025 | marketbeat.com

ProKidney Reports 78 Percent Gain in Q2

August 14, 2025 | theglobeandmail.com

Citi Reaffirms Their Buy Rating on ProKidney (PROK)

August 14, 2025 | theglobeandmail.com

ProKidney reports larger second-quarter loss as key studies continue

August 14, 2025 | journalnow.comJ

ProKidney Corp. Reports Q2 2025 Financial Results

August 13, 2025 | msn.com

ProKidney reports Q2 EPS (13c), consensus (14c)

August 12, 2025 | msn.com

ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

August 12, 2025 | globenewswire.com

ProKidney Corp. (NASDAQ:PROK) Receives Consensus Rating of "Hold" from Analysts

August 10, 2025 | marketbeat.com

ProKidney Corp. (PROK) - Yahoo Finance

August 9, 2025 | finance.yahoo.com

ProKidney And 2 Other Penny Stocks To Watch Closely

August 7, 2025 | finance.yahoo.com

ProKidney (NASDAQ:PROK) Trading Down 10.5% - What's Next?

August 7, 2025 | marketbeat.com

ProKidney (NASDAQ:PROK) Stock Price Up 10% - Should You Buy?

August 1, 2025 | marketbeat.com

ProKidney (PROK) to Release Quarterly Earnings on Friday

August 1, 2025 | marketbeat.com

ProKidney (NASDAQ:PROK) Stock Price Down 7.8% - What's Next?

July 29, 2025 | marketbeat.com

ProKidney Stock Skyrockets But Greensboro Is Still Empty Handed

July 25, 2025 | rhinotimes.comR

ProKidney Corp (PROK) Completes Re-domestication to Delaware amid Kidney Therapy Advancement

July 22, 2025 | msn.com

Meet the Biotech Stock That Rocketed 775% Higher

July 22, 2025 | fool.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK, IMVT, GMTX, and CPRX Company Descriptions

Catalyst Pharmaceuticals NASDAQ:CPRX

$20.63 -0.45 (-2.13%)

Closing price 03:59 PM Eastern

Extended Trading

$21.01 +0.38 (+1.84%)

As of 04:01 PM Eastern

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Gemini Therapeutics NASDAQ:GMTX

$60.35 +0.60 (+1.00%)

As of 08/22/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Immunovant NASDAQ:IMVT

$14.90 -0.34 (-2.26%)

Closing price 03:59 PM Eastern

Extended Trading

$14.90 0.00 (-0.01%)

As of 04:01 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

ProKidney NASDAQ:PROK

$2.35 -0.07 (-2.70%)

As of 04:00 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time